U.S. Markets closed

Wired News – AbbVie Presents New Undetectable Minimal Residual Disease Data from Phase-3 MURANO Trial of Venetoclax with Rituximab at 23rd European Hematology Association Annual Congress

Stock Monitor: NanoViricides Post Earnings Reporting

LONDON, UK / ACCESSWIRE / June 19, 2018 / If you want access to our free research report on AbbVie Inc. (NYSE: ABBV), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ABBV as the Company’s latest news hit the wire. On June 15, 2018, the Company announced that it has presented investigational data from a new analysis of undetectable minimal residual disease (uMRD) rates from the pivotal Phase-3 MURANO trial, assessing venetoclax in combination with rituximab (VenR) in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) during the 23rd European Hematology Association (EHA) Annual Congress, Stockholm, held on June 16, 2018. Register today and get access to over 1,000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for NanoViricides, Inc. (NYSE AMER: NNVC), which also belongs to the Healthcare sector as the Company AbbVie. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, AbbVie most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


83% Patients who Achieved uMRD at End of Combination Therapy with VenR were Progression-Free at 13.8 Months of Follow-Up

The international, multicenter, open-label, randomized Phase-3 MURANO study included a total of 389 patients with R/R CLL who had received at least one prior therapy. The primary endpoint of the study is investigator-assessed progression-free survival, and evaluation of safety of venetoclax in combination with rituximab, in 194 patients of median age 64.5 years, for up to two years; compared to bendamustine in combination with rituximab, in 195 patients of median age 66.0 years, for six months. Of the 121 patients who achieved uMRD (meaning less than one CLL cell in 10,000 white blood cells were detectable using a standardized test) at the end of combination therapy (EOCT), 83% maintained uMRD and were progression-free for a median of 13.8 months thereafter.

Data Supports a Correlation between uMRD and Improved Clinical Outcomes for CLL

Neil Gallagher, M.D., Ph.D., Head of Global Oncology Development at AbbVie, stated that the venetoclax data being presented at EHA adds to the growing body of evidence that supports a correlation between uMRD and improved clinical outcomes for patients with CLL. Gallagher added that the Company continues to investigate the correlation between uMRD and clinical outcomes following treatment with venetoclax alone, or in novel combinations, for the potential treatment of patients with CLL and other blood cancers.

About Chronic Lymphocytic Leukemia (CLL)

CLL is a type of cancer in which the bone marrow makes too many lymphocytes. Early on, there are typically no symptoms. Later non-painful lymph nodes swelling, feeling tired, fever, or weight loss for no clear reason may occur. Enlargement of the spleen and anemia may also occur, which worsens gradually. Risk factors include having a family history of the disease. CLL results in the buildup of B cell lymphocytes in the bone marrow, lymph nodes, and blood. These cells do not function well and crowd out healthy blood cells.

About VENCLYXTO® (Venetoclax)

Venetoclax, an oral B-cell lymphoma-2 (BCL-2) inhibitor, is indicated for the treatment of CLL in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor; and for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor. It is also being evaluated for the treatment of patients with various blood cancer types. Venetoclax is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, which is a member of the Roche Group, in the US and by AbbVie outside of the US. Together, the Companies are committed to BCL-2 research with venetoclax, which is currently being evaluated in Phase-3 clinical trials for the treatment of R/R CLL, along with studies in several other cancers.

About AbbVie Inc.

Founded in 2013 and headquartered in North Chicago, Illinois, AbbVie is a global, research and development (R&D) biopharmaceutical organization committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions.

Stock Performance Snapshot

June 18, 2018 - At Monday’s closing bell, AbbVie’s stock declined 1.09%, ending the trading session at $98.48.

Volume traded for the day: 6.43 million shares.

Stock performance in the previous six-month period – up 2.26%; past twelve-month period – up 38.61%; and year-to-date - up 1.83%

After yesterday’s close, AbbVie’s market cap was at $156.68 billion.

Price to Earnings (P/E) ratio was at 15.83.

The stock has a dividend yield of 3.90%.

The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Major industry.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors